By Business/Source
Currency:USD
2025/Q3
Stock NameRevenueRatio
Development and commercialization of therapies for patients with rare diseases51.3M100.00%
By Country/Region
Currency:USD
2024/FY
Stock NameRevenueRatio
United States96.11M73.86%
International34.02M26.14%